{"organizations": [], "uuid": "14d9b75d4669e3bd4254d0427bb67054bad01ddb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mallinckrodt-reports-on-fda-joint/brief-mallinckrodt-reports-on-fda-joint-advisory-committee-meeting-for-stannsoporfin-idUSFWN1SA1E7", "country": "US", "domain_rank": 408, "title": "Mallinckrodt Reports On FDA Joint Advisory Committee Meeting For Stannsoporfin", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.672, "site_type": "news", "published": "2018-05-04T06:57:00.000+03:00", "replies_count": 0, "uuid": "14d9b75d4669e3bd4254d0427bb67054bad01ddb"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mallinckrodt-reports-on-fda-joint/brief-mallinckrodt-reports-on-fda-joint-advisory-committee-meeting-for-stannsoporfin-idUSFWN1SA1E7", "ord_in_thread": 0, "title": "Mallinckrodt Reports On FDA Joint Advisory Committee Meeting For Stannsoporfin", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "mallinckrodt reports on fda joint advisory committee meeting for stannsoporfin", "sentiment": "negative"}, {"name": "mallinckrodt plc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - Mallinckrodt Plc:\n* MALLINCKRODT REPORTS ON FDA JOINT ADVISORY COMMITTEE MEETING FOR STANNSOPORFIN FOR THE TREATMENT OF NEWBORNS AT RISK OF DEVELOPING SEVERE JAUNDICE\n* FDA COMMITTEE RECOMMENDED RISK-BENEFIT PROFILE OF STANNSOPORFIN DOES NOT SUPPORT APPROVAL FOR TREATMENT OF NEWBORNS â‰¥35 WEEKS OF GESTATIONAL AGE\n* GIVEN THE OUTCOME OF MEETING, THE COMPANY IS EVALUATING ALTERNATIVES FOR THIS DEVELOPMENT PROGRAM Source text for Eikon:\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-04T06:57:00.000+03:00", "crawled": "2018-05-04T16:51:09.003+03:00", "highlightTitle": ""}